Liz Y Han

Liz Y Han

UNVERIFIED PROFILE

Are you Liz Y Han?   Register this Author

Register author
Liz Y Han

Liz Y Han

Publications by authors named "Liz Y Han"

Are you Liz Y Han?   Register this Author

33Publications

643Reads

17Profile Views

Current treatment and clinical trials in ovarian cancer.

Expert Opin Investig Drugs 2010 Apr;19(4):521-34

Royal Marsden Hospital, The Gynecology Unit, Department of Medicine, Sycamore House, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543781003647966DOI Listing
April 2010

Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.

J Reprod Med 2009 Apr;54(4):259-60

Department of Obstetrics and Gynecology, Georgetown University, Washington, D.C., USA.

View Article

Download full-text PDF

Source
April 2009

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.

Cancer Res 2007 Oct;67(19):9337-45

Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-4018DOI Listing
October 2007

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.

Cancer Res 2007 Feb;67(4):1757-68

Departments of Gynecologic Oncology and Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-3700DOI Listing
February 2007

EphA2 overexpression is associated with angiogenesis in ovarian cancer.

Cancer 2007 Jan;109(2):332-40

Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22415DOI Listing
January 2007

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.

Cancer Res 2007 Jan;67(1):281-8

Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-3282DOI Listing
January 2007

Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.

Cancer Biol Ther 2006 Oct 26;5(10):1369-74. Epub 2006 Oct 26.

Department of Gynecologic Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77230-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.10.3240DOI Listing
October 2006

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Cancer Biol Ther 2006 Oct 31;5(10):1357-60. Epub 2006 Oct 31.

Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.10.3225DOI Listing
October 2006

Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.

J Clin Oncol 2006 Feb 27;24(5):755-61. Epub 2005 Dec 27.

Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.9181DOI Listing
February 2006

Recurrent immature teratoma of the ovary: a case report of radical secondary cytoreduction with replacement of the aortic bifurcation.

Gynecol Oncol 2004 Dec;95(3):746-9

Department of Gynecologic Oncology, Cancer Hospital of Fudan University, 270 Dong-an Road, Shanghai 200032, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.08.007DOI Listing
December 2004